Program Agenda

Day 1 | Day 2 | Day 3

With Thanks to Our Sponsors

Patron

Patrons: Cyberonics, Danny Did, Pfizer, Sunovion, Upsher-Smith

Supporter

Supporters: Lundbeck, Medtronic, Supernus

Associate

Associates: Openconcept, UCB

Mission Advocate

Advocate: Neurovista

On February 2 – 4, 2012 in San Francisco, CA, the Epilepsy Therapy Project presented our 3rd biennial showcase of emerging and established companies presenting their strategies, candidates and development programs. You learned how anti-seizure product development is the optimal pathway for CNS therapeutic development because of well-characterized mechanisms, therapeutic approaches, and clear clinical endpoints for regulatory studies.

You were among small, mid, and major CNS companies who presented their strategies, product candidates and development programs to potential venture capital, private equity, pharma and biotech investors and partners.

Conference Agenda

Day 1 - Thursday February 2, 2012
7:00-8:00	Registration and Continental Breakfast
8:00-8:15	Welcome and Overview:	Warren Lammert and Jacqueline French, MD
8:15-8:45	2011 Epilepsy Pipeline Scorecard: Pipeline Advances and Challenges	Daniel Friedman, MD
*Session I: Are we getting closer?*
8:45-9:05	Where has epilepsy control improved in the last 30 years and what do we need today?	Dieter Schmidt, MD
9:05-9:25	Preclinical Testing: Getting out of the rut and how can we move faster?	Henrik Klitgaard, PhD
9:25-9:45	New paradigms in translational research	Frances Jensen, MD
9:45-10:15	Discussion
10:15-10:30	Networking Break
*Session II: Early Drug Pipeline: Proof of Principle through IND*
10:30-10:40	Developing Innovative Epilepsy Therapies in the Academic Setting	Michael A. Rogawski, MD, PhD
10:40-10:50	Inhaled Treatments to Stop Seizures Before they Spread	Michael A. Rogawski, MD, PhD
10:50-11:00	Galanin Receptor-2 Based Therapy NeuroAdjuvants, Inc.	Brian Klein, PhD
11:00-11:10	NTP Pipeline Development NeuroTherapeutics Pharma	Stephen D. Collins, MD. PhD
11:10-11:20	Adenosine releasing brain implants For Epilepsy Therapy Legacy Research Institute	Detlev Boison, PhD
11:20-11:30	CPP-115, The Next Generation GABA-AT Inhibitor Catalyst Pharmaceutical Partners, Inc.	Steven Miller, PhD
11:30-11:50	C-21191: Anticonvulsant and Antinociceptive Properties of a Novel Sub-type Selective GABA-A Agonist C-10068: Novel Morphinan Anticonvulsant with a Unique Pharmacological Profile Concert Pharmaceuticals	Philip B. Graham, PhD.
11:50-12:00	2DG Preclinical Development - An Update NeuroGenomeX, Inc.	Thomas Sutula, MD, PhD
12:00-12:10	XeriJect Diazepan for Emergency Treatment of Seizures Xeris Pharmaceuticals, Inc.	Steven Prestrelski, PhD
12:10-12:20	Galanin gene delivery for temporal lobe epilepsy Asklepios BioPharmaceutical, Inc.	Scott W.J. McPhee, PhD, MPH
12:20-12:30	Tonabersat Upsher-Smith Laboratories	H. Steve White, PhD
12:30-12:40	Huperzine Update	Steven C. Schachter, MD
12:40-2:00	Networking Lunch
*Session III: Early Device/Hybrid Product Pipeline: New Concepts and Initial Findings*
2:00-2:10	Improving Surgical Planning with Powerful Non-Invasive Dense Array EEG Electrical Geodesics, Inc.	Ann Bunnenberg, PhD., JD
2:10-2:20	Convenient and adaptable EEG Headset Advanced Neurometrics, Inc.	Eric A. Duff
2:20-2:30	ICV Dosing for Medication-Resistant Epilepsy	Robert Fisher, MD, PhD
2:30-2:40	A toxin-free in vivo assay for the discovery of antiepileptogenic and antiepileptic therapies	Braxton Norwood, PhD
2:40-2:50	Improving the development of promising drug candidates: preclinical solutions in a chronic mouse model of Mesial Temporal Lobe Epilepsy SynapCell SAS	Melanie Langlois, PhD
2:50-3:20	Networking Break
3:20-5:20	Epilepsy Therapy Project Shark Tank Competition: Immediate $50K grant award to winner of the best proposal for novel concept that will help people with epilepsy in the near term
5:25-7:00	Networking Reception and Celebration Honoring 2011 Lifetime Accelerator Award Recipient Honoree: Harvey Kupferberg, PhD

Day 2 - Friday February 3, 2012
7:00-8:10	Continental Breakfast
8:10-8:30	Epilepsy Study Consortium: Clinical Focus and Global Opportunity	Jacqueline French, MD
*Session IV: Opportunities for the future*
8:30-9:00	Inflammation as a target for antiepileptic and antiepileptogenic therapy: Human and animal evidence, theories, and the targets	Annamaria Vezzani, PhD
9:00-9:30	Update on the NINDS Anticonvulsant Screening Program	H. Steve White, PhD
9:30-10:00	Discussion
10:00-10:30	Networking Break
*Session V: Late Stage Devices*
10:30-10:40	Responsive Neurostimulation for Epilepsy: Update on the RNS® System Clinical Trials NeuroPace, Inc.	Martha J. Morrell MD
10:40-10:50	Cardiac-Based Seizure Detection: Implications for VNS Therapy Intervention and Event Logging Cyberonics, Inc.	Milton M. Morris, PhD
10:50-11:00	Visualase Laser Ablation in Neurosurgery Visualase, Inc.	Bill Hoffman
11:00-11:10	Transcranial Magnetic Stimulation in Clinical and Experimental Epilepsy	Alexander Rotenberg, MD., PhD
11:10-11:20	Preliminary Clinical Results of an Implantable Seizure Advisory System NeuroVista Corporation	W. Douglas Sheffield, VMD, PhD
11:20-11:30	DBS Therapy for Epilepsy Medtronic Neuromodulation Research	Jon Giftakis, PhD
11:30-11:40	Trigeminal Nerve Stimulation - an investigational therapy for Epilepsy and Mood disorders	Christopher DeGiorgio, MD
11:40-11:50	SmartWatch - Studies and Commercialization SmartMonitor	Anoo Nathan
11:50-12:15	Panel: Investor Climate and Regulatory Hurdles for Drugs and Devices Moderator: Casey Crawford Lynch, Managing Director, NeuroInsights Sami Hamadé, Partner, Aberdare Ventures Manuel O. Lopez-Figueroa, PhD, Vice President, Bay City Capital Heath Lukatch, PhD, Partner, Novo Ventures Anand Mehra, MD, Partner, Soffinova Ventures Sherrie Perkins, Director of New Business Development, Cyberonics Mark Simon, Advisor, Torreya Partners	Panel Discussion
12:15-1:30	Networking Lunch
*Session VI: Late Stage Drugs*
1:30-1:40	Eslicarbazepine Acetate (ESL) Sunovion Pharmaceuticals, Inc.	David Blum, MD
1:40-2:10	Lifecycle and Pipeline Projects Update: Vimpat, Keppra and Brivaracetam UCB BioSciences, Inc.	Babak Boroojerdi, MD., PhD., MBA
2:10-2:20	ONFI™ (Clobazam) Lundbeck, US	Deborah Lee, MD., PhD
2:20-2:30	Pregabalin Controlled Release Formulation Pfizer, Inc.	Verne Pitman, PharmD
2:30-2:40	Ganaxolone: A New Class of Treatment for Adjunctive Use in Partial Seizures Marinus Pharmaceuticals, Inc.	Gail M. Farfel, PhD
2:40-2:50	YKP 3089 SK LifeScience, Inc.	S. James Lee, PhD
2:50-3:00	VX-765	Jacqueline French, MD
3:00-3:10	Extended Release Oxcarbazepine Supernus Pharmaceuticals, Inc.	Paolo Baroldi, MD, PhD
3:10-3:30	Q&A / Discussion	Moderator: TBD
3:30-3:40	Closing remarks	Roger Porter, MD

Day 3 - Saturday February 4, 2012 - ETP Family Day - Pipeline Conference for General Public

Interested in learning about the changing world of epilepsy? Join us for ETP's Family Day for presentations about the Epilepsy Pipeline and emerging research and about new ways of thinking about epilepsy, new treatments and directions in care, using technology to manage your life with epilepsy and help others!

Objectives:

Appreciate the importance and challenges of living with epilepsy and developing new therapies and approaches.
Learn about new ways of looking at epilepsy and the brain.
Empower yourself to increase awareness of epilepsy and its consequences, how the Epilepsy Pipeline can help, and how you can make a difference.

8:00-9:00	Registration and Exhibits
9:00-9:10	Welcome and Overview
9:10-9:40	The Reality of Epilepsy: State of the Art	Steven C. Schachter MD, Harvard Medical School, Boston MA
9:40-10:20	Panel: New Ways of Understanding the Brain and Epilepsy Epilepsy as a Spectrum Disorder -Frances E. Jensen MD, Children's Hospital Boston, Boston MA What Do Our Genes Tell Us? -Daniel H. Lowenstein MD, University of California, Dept of Neurology, San Francisco CA
10:20-10:35	Challenges Through Our Eyes	Linda and Eric Warner Minneapolis, MN Amber Cooksey
10:35-10:50	Break, Exhibits
10:50-11:30	Epilepsy Medications and Alternative Therapies on the Horizon	Jacqueline French MD, New York University, New York, NY Steven C. Schachter MD Harvard Medical School, Boston, MA
11:30 - 12:15	Panel Discussion: SUDEP – What do we know and what we need to talk about Moderator: Joseph I. Sirven, MD, Mayo Clinic Arizona Panelists: Jeffrey Buchhalter MD, PhD, Phoenix Children's Hospital, Phoenix AZ Thomas Stanton, Danny Did Foundation Tamzin Jeffs, SUDEP Aware Lisa Lindahl, Entrepeneur John Barry, MD, Stanford University, San Francisco CA
12:15-1:00	Box Lunch and Exhibits
1:00-1:40	Devices and Surgery - Insights on Old and New Approaches	Robert Fisher MD, PhD, Stanford University, San Francisco CA Samantha Chartrau, Grafton WI, Mentor, epilepsy.com
1:40-2:20	Dietary Therapies and Wellness	Elizabeth Thiele MD, PhD, Massachusetts General Hospital, Boston MA; Heidi Pask, Stoneboro PA, Mentor, epilepsy.com
2:20-3:10	Reactor Panel: Insights from people with epilepsy Moderator: Mimi Callanan RN, MSN, CNS, Stanford University, San Francisco, CA Panelists: Dayna Breman, Los Angeles CA, Mentor, epilepsy.com D. Andrew Neff, Epilepsy Foundation of Northern California Amber Cooksey Chris Wilson, Albuquerque NM, Mentor, epilepsy.com
3:10-3:50	Tools you can use in managing epilepsy, the role of social networking	Patricia O. Shafer RN, MN, Beth Israel Deaconess Medical Center, Boston MA Samantha Chartrau, Grafton WI, Mentor, epilepsy.com Patricia Barnes, New Sharon ME, Kevin's Pyramids
3:50-4:00	Questions, Closing Remarks
4:00-5:00	Reception

Member Login

2012 Epilepsy Pipeline Update Conference